Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer
Clinical trial NCT02625441 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02625441
- Sponsor
- Helsinki University Central Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-01
- Primary completion
- 2025-06-01
- Enrollment
- 516
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.